The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064
作者:Jonathan Y. Bass、Richard D. Caldwell、Justin A. Caravella、Lihong Chen、Katrina L. Creech、David N. Deaton、Kevin P. Madauss、Harry B. Marr、Robert B. McFadyen、Aaron B. Miller、Derek J. Parks、Dan Todd、Shawn P. Williams、G. Bruce Wisely
DOI:10.1016/j.bmcl.2009.04.047
日期:2009.6
Starting from the known FXR agonist GW 4064 1a, a series of alternately 3,5-substituted isoxazoles was prepared. Several of these analogs were potent full FXR agonists. A subset of this series, with a tether between the isoxazole ring and the 3-position aryl substituent, were equipotent FXR agonists to GW 4064 1a, with the 2,6-dimethyl phenol analog 1t having greater FRET FXR potency than GW 4064 1a. (C) 2009 Elsevier Ltd. All rights reserved.